基本信息
浏览量:87
职业迁徙
个人简介
MSc in Pharmacy (UB, 1996), I completed my PhD in Dr. Albert Tauler's lab at the School of Pharmacy in the University of Barcelona, working on the role of PI3K/Akt signalling in the control of 6PF2K/Fru-2,6-BPase expression, a key enzyme in the regulation of the glycolytic flux in proliferative tissues.
After my PhD (UB, 2001, European PhD Mention) I joined Eric Lam's lab at the Cancer Research UK in Hammersmith Hospital, Imperial College London, where I was awarded a World Health Organization postdoctoral fellowship (IARC/OMS). My postdoctoral work was focused on the functional role of FOXO transcription factors in the response to chemotherapeutic agents such as Imatinib (Gleevec), and the molecular mechanisms whereby FOXOs regulate cyclin D2 and Bim expression.
In 2005 I was awarded a 'Ramón y Cajal' fellowship and joined the IUNICS at the University of the Balearic Islands. In late 2006, together with Dr. Villalonga, I contributed to establish a new research group: Cancer Cell Biology Group.
I am presently continuing my work on FOXO functions in the response to chemotherapeutic drugs. Specifically, I have started new projects in collaboration with clinical fellows to determine the functional role of the PI3K/Akt/FOXO pathway in the development of non-Hodgkin Lymphomas and its effector role in the response to new antitumoral agents.
My research career has been continuous since 1996. I have published 29 research articles, 8 of which as first or corresponding author, and a book chapter. Since 2007 I have been principal investigator in 2 research projects from Instituto de Salud Carlos III, 1 from the local government and 3 from private institutions. Also, my research group has participated in a national project from Programa Consolider-Ingenio 2010 (Ministerio de Economia y Competitividad, 2011-2016). As a member of UIB, I have organised 5 international meetings in translational oncology.
After my PhD (UB, 2001, European PhD Mention) I joined Eric Lam's lab at the Cancer Research UK in Hammersmith Hospital, Imperial College London, where I was awarded a World Health Organization postdoctoral fellowship (IARC/OMS). My postdoctoral work was focused on the functional role of FOXO transcription factors in the response to chemotherapeutic agents such as Imatinib (Gleevec), and the molecular mechanisms whereby FOXOs regulate cyclin D2 and Bim expression.
In 2005 I was awarded a 'Ramón y Cajal' fellowship and joined the IUNICS at the University of the Balearic Islands. In late 2006, together with Dr. Villalonga, I contributed to establish a new research group: Cancer Cell Biology Group.
I am presently continuing my work on FOXO functions in the response to chemotherapeutic drugs. Specifically, I have started new projects in collaboration with clinical fellows to determine the functional role of the PI3K/Akt/FOXO pathway in the development of non-Hodgkin Lymphomas and its effector role in the response to new antitumoral agents.
My research career has been continuous since 1996. I have published 29 research articles, 8 of which as first or corresponding author, and a book chapter. Since 2007 I have been principal investigator in 2 research projects from Instituto de Salud Carlos III, 1 from the local government and 3 from private institutions. Also, my research group has participated in a national project from Programa Consolider-Ingenio 2010 (Ministerio de Economia y Competitividad, 2011-2016). As a member of UIB, I have organised 5 international meetings in translational oncology.
研究兴趣
论文共 37 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
FEBS OPEN BIOno. SUPnan (2019): 31.0-31.0
引用0浏览0引用
0
0
Biochemical pharmacology (2016): 28-42
加载更多
作者统计
#Papers: 39
#Citation: 2363
H-Index: 18
G-Index: 29
Sociability: 5
Diversity: 3
Activity: 11
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn